Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects.
A patient with idiopathic thrombocytopenic purpura (ITP) developed T-cell lymphoma while undergoing steroid therapy. We examined the relationship between the patient's serum thrombopoietin (Tpo) level, platelet count, megakaryocyte number and CFU-Meg number during the second 5 d course of chemotherapy for lymphoma in which megakaryopoiesis switched from ITP phase to amegakaryocytic phase. The patient's platelet count was temporarily elevated but CFU-Meg numbers were markedly suppressed, and megakaryocyte numbers were decreased in this period, whereas serum Tpo level was not suppressed despite an increased platelet count, indicating that serum Tpo level is mainly regulated by megakaryocyte mass.
Nagasawa
T
T
Division of Haematology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
Hasegawa
Y
Y
Shimizu
S
S
Kawashima
Y
Y
Nishimura
S
S
Suzukawa
K
K
Mukai
H
H
Hori
M
M
Komeno
T
T
Kojima
H
H
Ninomiya
H
H
Tahara
T
T
Abe
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002452:Cell Count; D002454:Cell Differentiation / Q000502:physiology; D005260:Female; D006410:Hematopoiesis / Q000502:physiology; D006801:Humans; D016399:Lymphoma, T-Cell / Q000139:chemically induced / Q000188:drug therapy; D008533:Megakaryocytes / Q000473:pathology*; D008875:Middle Aged; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood* / Q000188:drug therapy; D013256:Steroids / Q000627:therapeutic use; D013926:Thrombopoietin / Q000097:blood*
D013256:Steroids; D013926:Thrombopoietin